PPARG and pulmonary arterial hypertension: Similarly to humans, several animal studies reported improved pulmonary hypertension and right ventricle (RV) hypertrophy [116], pulmonary hypertension prevention [117, 118] and pulmonary vasculature remodeling [119] by PPAR-γ-dependent inhibition of transcription factors NFAT and NF-kB [120].